CollPlant Expands STEMCELL Technologies Partnership to Include Clinical and Commercial Applications of Plant-Derived Collagen
Key Insights
CollPlant Biotechnologies (search) has expanded its collaboration with STEMCELL Technologies (search) to include clinical development and commercial-scale manufacturing of its plant-derived recombinant human collagen (search) (rhCollagen (search)).
The amended agreement extends beyond research applications, positioning CollPlant's rhCollagen (search) as a viable alternative to animal-sourced materials for biomanufacturing applications.
STEMCELL Technologies (search), which supports life sciences research with over 2,500 specialized reagents and tools, will now utilize CollPlant's proprietary rhCollagen (search) technology in clinical and commercial domains.
CollPlant Biotechnologies (search) has significantly expanded its partnership with STEMCELL Technologies (search), extending the use of its proprietary plant-derived recombinant human collagen (search) (rhCollagen (search)) from research applications into clinical development and commercial-scale manufacturing. The announcement, made on June 9, 2025, marks a strategic milestone for the regenerative medicine company's novel collagen technology.
Partnership Expansion Details
The amended agreement broadens the scope of collaboration between CollPlant (NASDAQ: CLGN) and STEMCELL Technologies (search), a biotechnology company that develops specialized cell culture media, tools, and services for stem cell biology, regenerative medicine, immunology, and related life sciences research. STEMCELL Technologies supports global research with more than 2,500 specialized reagents, tools, and services used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research.
"Expanding our partnership with STEMCELL Technologies (search) into clinical and commercial domains reflects both the evolving needs of the life sciences market and the strength of our novel technology," commented Yehiel Tal, Chief Executive Officer of CollPlant. "This milestone highlights our shared commitment to advancing safer, more effective, and sustainable solutions for researchers and biomanufacturers alike."
Technology and Market Position
CollPlant's rhCollagen (search) is produced using the company's proprietary plant-based genetic engineering technology, offering what the company positions as a viable alternative to animal-sourced materials. Tal emphasized that this approach "aligns with growing industry priorities around safety, consistency, and ethical sourcing."
The company focuses on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. CollPlant's products address indications across diverse fields including tissue repair, aesthetics, and organ manufacturing. The company's Type I recombinant human collagen (search) serves as the foundation for its regenerative and aesthetic medicine applications.
Strategic Partnerships and Commercial Development
CollPlant has established significant partnerships in the aesthetic medicine space, including a 2021 development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie (search) company described as the global leader in the dermal filler market. This partnership demonstrates the commercial viability and market acceptance of CollPlant's rhCollagen (search) technology platform.
The expansion with STEMCELL Technologies (search) represents a strategic move into clinical and commercial manufacturing applications, potentially broadening the market reach for CollPlant's plant-derived collagen technology beyond its current focus areas.